279 related articles for article (PubMed ID: 36747202)
21. CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma.
Xiang H; Long L; Yao Y; Fang Z; Zhang Z; Zhang Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819830751. PubMed ID: 30862264
[TBL] [Abstract][Full Text] [Related]
22. Advances in endovascular therapy to treat primary hepatocellular carcinoma.
Guo Z; Yu H; Liu C; Si T; Yang X; Zhang W; Xu Y; Li Y
Drug Discov Ther; 2015 Oct; 9(5):342-51. PubMed ID: 26632543
[TBL] [Abstract][Full Text] [Related]
23. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis.
Ni JY; Xu LF; Wang WD; Sun HL; Chen YT
World J Gastroenterol; 2014 Dec; 20(45):17206-17. PubMed ID: 25493037
[TBL] [Abstract][Full Text] [Related]
24. Safety and effectiveness of new embolization microspheres SCBRM for intermediate-stage hepatocellular carcinoma: A feasibility study.
Liu YS; Lin XZ; Chen CY; Chiu YC; Kang JW; Tsai HW; Hung HY; Ho CM; Ou MC
Bosn J Basic Med Sci; 2021 Jun; 21(3):339-345. PubMed ID: 32841586
[TBL] [Abstract][Full Text] [Related]
25. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment.
Tsochatzis EA; Germani G; Burroughs AK
Semin Oncol; 2010 Apr; 37(2):89-93. PubMed ID: 20494700
[TBL] [Abstract][Full Text] [Related]
26. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
27. Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma.
Jia G; Van Valkenburgh J; Chen AZ; Chen Q; Li J; Zuo C; Chen K
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Mar; 14(2):e1749. PubMed ID: 34405552
[TBL] [Abstract][Full Text] [Related]
28. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.
Ou HY; Wu YN; Yu CY; Chen CL; Hsu HW; Weng CC; Leung-Chit Tsang L; Huang TL; Tong YS; Lim WX; Cheng YF
J Vasc Interv Radiol; 2020 Nov; 31(11):1784-1791. PubMed ID: 33023805
[TBL] [Abstract][Full Text] [Related]
29. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.
Lee EW; Khan S
Clin Mol Hepatol; 2017 Dec; 23(4):265-272. PubMed ID: 29113030
[TBL] [Abstract][Full Text] [Related]
31. Transarterial therapies for hepatocellular carcinoma.
Sangro B; D'Avola D; Iñarrairaegui M; Prieto J
Expert Opin Pharmacother; 2011 May; 12(7):1057-73. PubMed ID: 21470073
[TBL] [Abstract][Full Text] [Related]
32. Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients.
Zhao G; Liu S; Chen S; Ren Z; Li C; Bian J; Wu J; Zhou J; Zhang Y
Drug Deliv; 2021 Dec; 28(1):1356-1362. PubMed ID: 34180755
[TBL] [Abstract][Full Text] [Related]
33. [A case report of unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus responding to DSM-TACE (degradable starch microspheres-transcatheter arterial chemoembolization)].
Kirihara M; Nagashima M; Higuchi K; Tahira H; Tajima M
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2705-7. PubMed ID: 21224686
[TBL] [Abstract][Full Text] [Related]
34. [Complications after TACE in HCC - complications after transarterial chemoembolization (TACE) in hepatocellular carcinoma].
Schneeweiß S; Horger M; Ketelsen D; Ioanoviciu SD
Rofo; 2015 Feb; 187(2):79-82. PubMed ID: 25629286
[No Abstract] [Full Text] [Related]
35. Current concepts in transarterial chemoembolization of hepatocellular carcinoma.
Huppert P
Abdom Imaging; 2011 Dec; 36(6):677-83. PubMed ID: 21674193
[TBL] [Abstract][Full Text] [Related]
36. Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma.
Delhaye C; Hendlisz A; Vouche M
Curr Opin Oncol; 2019 Jul; 31(4):339-345. PubMed ID: 30896451
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic advances for patients with intermediate hepatocellular carcinoma.
Sun JY; Yin T; Zhang XY; Lu XJ
J Cell Physiol; 2019 Aug; 234(8):12116-12121. PubMed ID: 30648254
[TBL] [Abstract][Full Text] [Related]
38. DEB-TACE: a standard review.
Melchiorre F; Patella F; Pescatori L; Pesapane F; Fumarola E; Biondetti P; Brambillasca P; Monaco C; Ierardi AM; Franceschelli G; Carrafiello G
Future Oncol; 2018 Dec; 14(28):2969-2984. PubMed ID: 29987957
[TBL] [Abstract][Full Text] [Related]
39. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review.
Idée JM; Guiu B
Crit Rev Oncol Hematol; 2013 Dec; 88(3):530-49. PubMed ID: 23921081
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of drug-eluting bead-transcatheter arterial chemoembolization using 100-300 μm versus 300-500 μm CalliSpheres microspheres in patients with advanced-stage hepatocellular carcinoma.
Yang T; Qin W; Sun X; Wang Y; Wu J; Li Z; Ji F; Zhang L; Liu W
J Cancer Res Ther; 2020; 16(7):1582-1587. PubMed ID: 33565503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
